Sutimlimab (Enjaymo)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Mechanism of action

Anti-C1s antibody

Diseases for which it is used

History of changes in FDA indication

  • 2/4/2022: Approved to decrease the need for red blood cell transfusion due to hemolysis (red blood cell destruction) in adults with cold agglutinin disease (CAD). (Based on CARDINAL)

History of changes in EMA indication

  • 11/15/2022: Initial authorization

Also known as

  • Code name: BIVV009
  • Generic name: sutimlimab-jome
  • Brand name: Enjaymo